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Limin Long1†, Guoqing Huang2†, Hongyi Zhu3, Yonghong Guo1, Youshuo Liu1 and Jirong Huo3*Abstract
Background: Colorectal cancer (CRC) is the most common digestive system malignancy. The molecular events
involved in the development and progression of CRC remain unclear. Recently, more and more evidences have
showed that deregulated miRNAs participate in colorectal carcinogenesis.
Methods: The expression levels of miR-138 were first examined in CRC cell lines and tumor tissues by real-time
PCR. The in vitro and in vivo functional effects of miR-138 were examined further. Luciferase reporter assays were
conducted to confirm the targeting associations. Kaplan-Meier analysis and log-rank tests were performed to
estimate the overall survival and disease free survival rate.
Results: miR-138 was found to be down-regulated in human colorectal cancer tissues and cell lines. Ectopic
expression of miR-138 resulted in a dramatic inhibition of CRC migration and invasion in vitro and in vivo. Twist
basic helix-loop-helix transcription factor 2 gene (TWIST2) was identified as one of the functional target. Restoration
of miR-138 resulted in a dramatic reduction of the expression of TWIST2 at both mRNA and protein levels by
directly targeting its 3′-untranslated region (3′UTR). Up-regulation of TWIST2 was detected in CRC tumors compared
with adjacent normal tissues (P < 0.001) and is inversely correlated with miR-138 expression. We also identified that
down-regulation of miR-138 was associated with lymph node metastasis, distant metastasis, and always predicted
poor prognosis.
Conclusion: These data highlight a pivotal role for miR-138 in the regulation of CRC metastasis by targeting TWIST2,
and suggest a potential application of miR-138 in prognosis prediction and CRC treatment.
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Colorectal cancer (CRC) is one of the most common di-
gestive system tumors with high morbidity and mortality
[1]. Recent progress in diagnosis and therapy methods
has helped to cure this disease of many patients at early
stages, but the prognosis for patients with advanced dis-
ease or metastasis is still very poor. Therefore, further
investigations on the molecular pathogenesis of CRC and
finding effective biomarkers were needed to distinguish
patients with or without high metastatic risk followed by
appropriate therapy. A series of studies had revealed that
microRNAs (miRNAs) can regulate the expression of a
variety of genes pivotal for tumor development and play* Correspondence: hjr_198@hotmail.com
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reproduction in any medium, provided the orimportant roles in the process of cancer migration and
invasion [2-4].
miRNAs are 21- to 23-nucleotide, endogenous non-
coding RNAs that negatively regulate target gene expres-
sions by binding to its 3′UTR regions, leading to mRNA
degradation or inhibiting translation into protein. miR-
NAs were reported to be associated with the pathogen-
esis of many human cancers [5], such as miR-124 with
hepatocellular carcinoma cell [6], miR-30e* with human
glioma [7], miR-125b with breast cancer [8], and so on.
This result also applies to CRC, a subset of miRNAs was
found to be aberrantly expressed in CRC [9-11]. How-
ever, the particular molecular mechanisms through
which miRNAs mediate colorectal carcinogenesis and
metastasis are still largely unknown. So the identifica-
tion and characterization of the role of novel miRNAs
in CRC may provide new insight into understanding thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Koji Okamoto et al. report, miR-138 was reduced
expressed in the metastases in their experimental
models and others found that it may be involved in
ovarian cancer and non-small cell lung cancer metasta-
sis [11-13], which suggested that miR-138 might play an
important role in CRC progression.
In this study, we first detected the expressions of miR-
138 in CRC tissues and cell lines, and a series of in vitro
and in vivo studies were then conducted to investigate
the mechanisms and impact of miR-138 in CRC. By bio-
informatics analysis (TargetScan and MiRanda) and ex-
perimentally validation, we found TWIST2 was a direct
target of miR-138 and miR-138 can inhibit CRC metasta-
sis by targeting TWIST2. Finally, we find reduced expres-
sion miR-138 is usually associated with poor prognosis
with CRC patients by statistical analysis.Materials and methods
Cell culture
The human colorectal cell lines LoVo, DLD1, HCT116,
SW620, HT29 and SW116 were obtained from the Ameri-
can Type Culture Collection (Manassas, VA, USA). HT29
were cultured in McCoy’s 5A medium (Invitrogen; Life
Technologies, Carlsbad, CA, USA), LoVo, HCT116,
SW620 and SW116 were cultured in RPMI 1640 con-
taining 10% fetal bovine serum (Sigma-Aldrich, St.
Louis, MO, USA), and DLD1 were grown in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 (Gibico, USA)
supplemented with 10% fetal bovine serum (Sigma-
Aldrich, St. Louis, MO, USA). All the cells were cul-
tured in a humidified 37°C incubator supplemented
with 5% CO2.Human samples
Paired resected surgical specimens from primary tu-
mors were obtained from CRC patients who underwent
initial surgery at The Second Xiangya Hospital, Changsha,
according to a standard protocol, before any thera-
peutic intervention. The adjacent normal tissues at least
6 cm distant from the tumor were also taken. The eight
normal tissues are the adjacent normal tissues from the
36 patients group (Stage I: one case; Stage II: three
cases; Stage III: three cases; Stage IV: one cases). Fol-
lowing excision, tissue samples were immediately snap-
frozen in liquid nitrogen and stored at −80°C until RNA
extraction. The remaining tissue specimens were fixed
in 10% formalin and embedded in paraffin for routine
histological examination and IHC analysis. All subjects
provided informed consent before specimen collection.
The study protocol was approved by the Ethics Com-
mittee of The Second Xiangya Hospital of Central
South University.RNA isolation and quantitative real-time PCR
Total RNA from cells and tissues was isolated using
TRIzol reagent (Invitrogen, Carlsbad, California, USA)
and was eluted in 50 μL nuclease free water. RNA con-
centration was measured by Nanodrop 2000 (Thermo
Fisher Scientific, Wilmington, DE, USA). Real-time PCR
were performed using the TaqMan MicroRNA Assay Kit
(Applied Biosystems). Real-time PCR was performed
using the Applied Biosystems 7900 Fast Real-Time PCR
system (Applied Biosystems, Foster City, California,
USA). The comparative cycle threshold (Ct) method was
used to calculate the relative abundance of miRNA com-
pared with RNA U6 (RNU6B) expression (fold difference
relative to RNU6B).
Western blot analysis
Total cellular protein was extracted and protein concen-
tration was measured by the Bradford DC protein assay
(Bio-Rad, Hercules, CA, USA). Then, a total of 50 μg
protein was separated by SDS–PAGE and transferred to
a polyvinylidene fluoride (PVDF) membrane. Membranes
were incubated with primary antibodies. Primary anti-
bodies included as follows: Twist2 (1:1,000, CST, USA) β-
action (1:2,000, Santa Cruz Biotechnology, USA). The
secondary antibody was a goat anti-mouse antibody
(1:2000, Santa Cruz Biotechnology, USA). Proteins were
visualized using the ECL procedure (Amersham Biosci-
ences, USA). All experiments were performed three times.
Colony formation assay
Cells (1 × 105/well) were plated in a 24-well plate and
transfected with miR-138 or control microRNA at
20 nmol/L by using lipofectamine 2000 (Invitrogen; Life
Technologies). After 48 h, the cells were collected and
seeded (500–1,000/ well) in a fresh six-well plates. After
12 days, visible colonies were fixed and stained with
crystal violet.
Vector construction and dual-luciferase reporter assay
For luciferase assays, the potential miR-138 binding site
in the TWIST2 3′UTR was predicted at position 375–
382 from the stop codon site of TWIST2 by TargetScan
(www.targetscan.org) and miRanda (www.microRNA.org).
Sequence of the 50-bp segment with the wild-type or mu-
tant seed region was synthesized and cloned into the Xba I
site of a pGL3-Control vector (Promega, USA) down-
stream from the luciferase stop codon; the new vectors
were designated pGL3-TWIST2-WT and pGL3-TWIST2-
MUT, respectively. The 293 T cells (1.5 × 105 cells/well)
were seeded in a 24-well plate and co-transfected 18 h later
with pGL3-Control (0.4 mg) or pGL3-TWIST2-WT
(0.4 mg) or pGL3-TWIST2-MUT (0.4 mg), pGL4.73 vector
(a control Renilla luciferase vector, 50 ng, Promega, USA),
and miR-138 (20 nM) or control microRNA (20 nM) using
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vested 48 h after transfection, and luciferase activities were
analyzed by the Dual-Luciferase Reporter Assay System
(Promega, USA).
In vivo assays
Female athymic BABL/c nude mice (4–6 weeks old)
were purchased from the Experimental Animal Center
of Guangdong Province (Guangzhou, China). One mil-
lion HCT116-miR138 or HCT116-control stable cells
were injected into the lateral tail veins of each nude
mouse at a density of 1.0 × 107 cells/ml. The animals were
sacrificed, and their lungs were dissected and paraffin em-
bedded after 11 weeks. Transverse sections (4–6 μm) of
the lung were stained with hematoxylin and eosin (HE).
Metastatic nodules were counted in a double-blind man-
ner under microscopy, as described previously [14]. The
animal studies and the experimental protocol were con-
ducted in accordance with the current Chinese regulations
and standards on the use of laboratory animals.
Lentivirus packaging and stable cell line establishment
miR-138 and control microRNA precursor sequences
were amplified from human genomic DNA and cloned
into the BamH I and Mfe I site of the lentiviral vector
pEZX-MR03 (GeneCopoeiaTM) (pLV-miR-138, pLV-miR-
control). Viruses were packaged in 293 T cells. Lenti-Pac
HIV Expression Packaging Kit and pLV-miR-138 (or con-
trol) were co-transfected using EndoFectin Lenti transfec-
tion reagent following the manufacturer’s instruction
(GeneCopoeiaTM). 293 T cells were cultured in DMEM
with 5% FBS in a 37°C incubator with 5% CO2. Forty-eight
hours after transfection, the supernatant was harvested,
filtered and cleared by centrifugation at 500 × g for
10 min. Three days after infection, 2 μg/ml puromycin
was added to the culture media to select the cellFigure 1 miR-138 is commonly down-regulated in primary colorectal
36 primary colorectal tumors compared with their adjacent normal tissues.
significant difference in miR-138 level between paired samples. (B) The exp
colon tissues (n = 8) by quantitative RT-PCR with RNU6B as an internal contpopulations infected with the lentivirus for 2 weeks.
The cell line expressing microRNA-138 stably was
named HCT116-miR138; the control vector cell line
was named HCT116-control. The expression of miR-
138 was detected by real-time PCR in these two cell
lines as described above.Cell migration and invasion assays
Cell migration and invasion activity was assessed by
using a specialized Chamber (BD Biosciences) with or
without BD BioCoat Matrigel according to the manufac-
turer’s instructions. Cells (5 × 104 cells/mL) were loaded
into chamber inserts containing an 8-μm pore size
membrane with or without a thin layer matrigel matrix.
Cells migrating to the lower surface of the membrane
during 24 or 48 h were fixed with 100% methanol and
non-invading cells on the upper surface of the mem-
brane were removed. The membranes, with migrated
cells, were then stained with crystal violet, scanned, and
digital images were obtained with a microscope. The
number of migrated and invasive cells was then deter-
mined for 5 independent fields under a microscope. The
mean of triplicate assays for each experimental condition
was used for analysis.Statistical analysis
Data were expressed as mean ± standard deviation (SD).
The statistical significance of the studies was analyzed
using Student’s t test (two-tailed). To conduct survival
analysis, we included all of the CRC patients in a
Kaplan-Meier analysis. A log rank test was used to com-
pare different survival curves. All statistical analyses
were performed using SPSS 13.0 software package. The
probability of P < 0.05 was considered to be statistically
significant.cancer tissues and colon cancer cell lines. (A) Levels of miR-138 in
The miR-138 level is normalized to RNU6B, and the P value indicated a
ression level of miR-138 in eight colon cancer cell lines and normal
rol. *P < 0.05, **P < 0.01.
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miR-138 was down-regulated in CRC cell lines and
primary CRC tissues
We first examined the expression level of miR-138 in 36
human CRC tumor samples and paired normal colorec-
tal tissues. Consistent with our exception, there was a 2–
3 fold decrease in the expression level of miR-138 in the
36 tumors than in their paired normal tissues (P < 0.001)Figure 2 Effect of miR-138 on migration, invasion and colony formati
in HCT116 cells by real-time PCR. ***P < 0.001 (B and C) Overexpression of
Representative transwell results for control-transfected and miR-138-transfe
miR-138 can inhibit the colony formation of CRC cell lines. Representative c
transfected HCT116 cells were shown. **P < 0.01.(Figure 1A). Among these paired samples, 86.1% (31/36)
of the CRC samples showed lower miR-138 levels than
in the adjacent normal tissues (see Figure 1A). We also
examined miR-138 expression level in six CRC cell lines
(LoVo, DLD1, HCT116, SW620, HT29, SW116) and ob-
served that miR-138 was down-regulated in all six CRC
cell lines relative to the normal primary colon cells from
eight normal tissues (Figure 1B).on in CRC cell lines. (A) Overexpression of miR-138 was demonstrated
miR-138 can inhibit the migration and invasion of CRC cell lines.
cted HCT116 cells were shown. **P < 0.01 (D and E) Overexpression of
olony formation results for control-transfected and miR-138-
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formation, migration and invasion in vitro
To explore the effect of overexpression of miR-138 on
the tumorigenesis,motility and invasive capacity of CRC
cells, transwell assays were performed. HCT116 cells
transfected with miR-138 mimics or control microRNA
were seeded into the chambers with or without matrigel,
and their migratory and invasive potential were deter-
mined after 24 h, 36 h culture. Increased expression of
miR-138 in HCT116 cells following transfection was con-
firmed via real-time PCR (Figure 2A). The results showed
that the migratory capacity of HCT116 cells overexpress-
ing miR-138 was reduced by 60.7% compared with the
control groups (invasive capacity was reduced by 57.5%)
(Figure 2B, C). We also evaluated the colony formation
ability of HCT116 cells that had been transfected with
miR-138 and or microRNA. The results showed that the
miR-138-transfected cells formed considerably fewer andFigure 3 TWIST2 is a direct functional target of miR-138. (A) The cons
inserted into the C-terminal of the luciferase gene to generate pGL3-TWIST
138 down-regulated the TWIST2 mRNA level in HCT116 cells, as determine
protein level in HCT116 cells, as determined by Western Blot. The TWIST2 p
intensities. (D) miR-138 targets the wild-type but not the mutant 3′UTR of
vector) or reporters constructed containing either wild-type or mutant TWIST2
reporter. The luciferase activity assay was repeated three times. **P < 0.01. (E)
compared with their adjacent normal tissues (n = 36). (F) Correlation between
P = 0.0039, R2 = 0.2608. n = 36 (G) Rescue assays using HCT116 cells co-transfesmaller colonies than control microRNA-transfected cells
(Figure 2D), indicating a growth-inhibitory role of miR-
138 in CRC cells (Figure 2D, E).
TWIST2 was a direct target of miR-138 which inhibited its
expression via binding to its 3′UTR
It is accepted that miRNAs exert their function by regu-
lating the expression of their downstream target genes.
On the basis of two major prediction softwares, Targets-
can (http://www.targetscan.org) and miRNA (http://www.
microrna.org), we find that the 3′UTR of twist basic helix-
loop-helix transcription factor 2 gene (TWIST2) contains
a complementary site for the seed region of miR-138, and
may be a potential target of miR-138 (Figure 3A). To
validate the miRNA-target interaction and determine if
miR-138 affects TWIST2 expression in the intracellular
environment in CRC, the expression of TWIST2 was eval-
uated in HCT116 and SW620 cells following transfectionerved miR-138 binding sequence of TWIST2 or its mutated form was
2-WT or pGL3-TWIST2-MUT, respectively. (B) Ectopic expression of miR-
d by quantitative real-time PCR. (C) miR-138 decreased the TWIST2
rotein band intensities were quantified and normalized to β-actin
TWIST2. miR-138 was cotransfected with pGL3-Control(the empty
3′UTR into 293 T cells. pGL3-Control was used as an internal control
Levels of TWIST2 mRNA is up-regulated in primary colorectal tumors
TWIST2 protein expression and miR-138 expression in CRC tissues.
cted with Vector-TWIST2 or Vector and miR-138 or Control. **P < 0.01.
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transfection efficiency was determined by real-time RT-
PCR (data not shown). Transfection of miR-138 resulted
in significant reduction of TWIST2 mRNA (Figure 3B)
and protein (Figure 3C) expression by real-time RT-PCR
and Western blotting analysis, respectively. To further test
the specific regulation through the predicted binding sites,
we constructed a reporter vector consisting of the lucifer-
ase coding sequence followed by the 3′UTR of TWIST2
(wild type and mutant type) (Figure 3A). Cotransfection
experiments showed that miR-138 decreased the lucifer-
ase activity of wild type for 45%, but this was not observed
on mutant type (Figure 3D), indicating that TWIST2 is a
direct target of miR-138 through binding to its 3′UTR.
TWIST2 is up-regulated in primary CRC tissues and its
expression correlates with miR-138 expression in CRC
TWIST2 was reported to be a potential oncogene in hu-
man cancers [15]. To corroborate the potential import-
ance of TWIST2 in primary CRCs, we compared the level
of TWIST2 expression in 36 paired tumors versus the sur-
rounding normal tissues. The expression of the TWIST2Figure 4 Exogenetic expression of miR-138 suppresses CRC cell meta
miR-138. The expression of miR-138 was markedly increased in the lentivira
compared with the control stable cell line HCT116-Control. **P < 0.05. (B) R
metastatic nodules are indicated with arrows. (C) Representative results of
shown. Metastatic nodules are indicated with arrows. (D) Number of metas
a microscope. **P < 0.01, n = 8.mRNA accessed by real-time PCR was significantly in-
creased in CRC tumors by about 3 fold compared with the
adjacent normal tissues (P < 0.001; Figure 3E). TWIST2 is
overexpressed in 88.9% (32/36) of tumors compared with
their normal counterparts (see Figure 3E).
To further evaluate the correlation between TWIST2
and miR-138 expression in primary CRCs, we compared
the expression of TWIST2 and miR-138 in 36 primary
CRCs. Expression of TWIST2 and miR-138 exhibited a
significant inverse correlation (P = 0.0039, R2 = 0.2608;
Figure 3F), further supporting the miR-138 target status
of TWIST2.
miR-138 inhibits CRC cell motility by targeting TWIST2
To determine whether TWIST2 is involved in the miR-
138-induced inhibition of migration and invasion, we per-
formed rescue assays. As shown in Figure 3G, concomitant
overexpression of miR-138 and TWIST2 nullified the in-
hibitory effect of miR-138 on the cell migratory ability of
HCT116 cells compared with cells transfected with miR-
138 and the empty expression vector groups (p < 0.01).
However, there was no significant difference betweenstasis in vivo. (A) Establishment of the stable cell lines overexpressing
l vector-mediated miR-138-expressing stable cell line HCT116-miR138
epresentative lungs subjected to the indicated treatments. The
hematoxylin and eosin staining of metastatic nodules in the lung are
tatic nodules in the lungs of mice. The nodules were examined under
Table 1 The correlation between miR-138 expression and












≤56 93 44(47.3%) 49(52.7%) 0.510
>56 94 49(52.1%) 45(47.9%)
Sex
male 104 55(52.9%) 49(47.1%) 0.335
female 83 38(45.8%) 45(54.2%)
CEA Level
0 ~ 5 ng/ml 99 40(40.4%) 59(59.6%) 0.428
>5 ng/ml 88 32(36.4%) 56(63.6%)
CA199 Level
0 ~ 35 u/ml 136 65(47.8%) 71(52.2%) 0.254
>35 u/ml 47 27(57.4%) 20(42.6%)
Tumor Site
Colon 101 47(46.5%) 54(53.5%) 0.343
Rectum 86 46(53.5%) 40(46.5%)
Tumor Size (cm)
≤5 122 60(49.2%) 62(50.8%) 0.466
>5 62 29(46.8%) 33(53.2%)
Differentiation
Well/Moderate 144 61(42.4%) 83(57.6%) 0.209
Poor 43 27(62.8%) 16(37.2%)
pN
0 109 37(33.9%) 72(66.1%) 0.000*
≥1 78 56(71.8%) 22(28.2%)
pT
T1 + T2 47 27(46.9%) 20(53.1%) 0.105
T3 + T4 141 79(56.0%) 62(44.0%)
Distant metastasis
M0 161 79(49.1%) 82(50.9%) 0.002*
M1 26 22(84.6%) 4(15.4%)
*χ2 Test.
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pcDNA3.1-TWIST2 and the group that co-transfection
miR-138 with pcDNA3.1-TWIST2 (Figure 3G). These re-
sults demonstrated that miR-138 can inhibit CRC cell mi-
gration and invasion by targeting TWIST2.
miR-138 inhibits CRC cell metastasis in vivo
To further investigate the role of miR-138 involved in
CRC metastasis in vivo, we constructed a lentivirus vector
to mediate the expression of miR-138 and established two
stable cell lines, which were named HCT116-miR138 and
HCT116-control (Figure 4A). Real-time PCR results
showed that HCT116-miR138 cells expressed 13 fold
miR-138 than control cells HCT116-control, indicating
the construction was successful (Figure 4A). Then, we im-
planted HCT116-miR138 and HCT116-control cells into
nude mice through the lateral tail vein respectively. As
shown in Figure 4B, mice injected with HCT116-
control cells formed larger metastates in the lungs com-
pared with the HCT1116-miR138 cells (Figure 4B). The
HE results showed that most of the mice injected with
the HCT116-control cells displayed a large number of
metastatic lung nodules after eleven weeks of growth. In
contrast, injection of HCT116-miR138 cells generated
fewer metastatic nodules than were observed in the
controls (Figure 4C). And the results is statistical sig-
nificance (Figure 4D).
Correlations between miR-138 expressions and
clinicopathological characteristics and prognosis
To further investigate the clinicopathological and prog-
nostic significance of miR-138 levels in patients with
CRC, miR-138 levels were examined via real-time PCR
in 187 tumor tissues and paired normal tissues. And
miR-138 expression was divided into high or low expres-
sion group according to the median value. Therefore, pa-
tients with high or low miR-138 expression were 94 and
93, respectively. As shown in Table 1, no significant dif-
ferences were observed between miR-138 expressions
and age, sex, CEA level, CA199 level, tumor site, tumor
Size, differentiation, and Local invasion. But, miR-138
expression is significant correlated with the patient’s
lymph node metastasis and distant metastasis. Using
Kaplan–Meier method and log-rank test, the overall
survival (OS, Figure 5A) and disease-free survival (DFS,
Figure 5B) of CRC patients with high miR-138 expression
were both significantly longer than those with low miR-
138 expression.
Discussion
Metastasis is widely recognized as a poor prognostic
factor in cancer. MicroRNAs have recently been dem-
onstrated to potentially play a significant role in the
progression of carcinogenesis [16]. To date, lots ofdifferent miRNAs regulate many known oncogenic and
tumor suppressor pathways involved in the pathogen-
esis of CRC. For example, miR-192, miR-31 and miR-21
induce CRC cells resistance to 5-fluorouracil (5-FU) and
may be important clinical markers of chemotherapy effi-
cacy in colorectal cancer [17-19]. The miR-200 family
suppresses the zinc finger E-box binding homeobox to
promote CRC cell EMT and invasion [20]. In this work,
we have started to shed light on the importance of miR-
138 in CRC metastasis. While some studies have found
miR-138 might be a potential tumor suppressor in some
types of cancers, including ovarian cancer, head and
Figure 5 Kaplan–Meier analysis of overall survival and disease-free survival for patients with miR-138 high or low expressions. Overall
survival (OS) (A) and disease-free survival (DFS) (B) curves for two groups defined by low and high expression of miR-138 in patients with CRC.
The patients with low miR-138 expression had a significantly worse OS (P < 0.01) and DFS (P < 0.01) survival rate than those with high
miR-138 expression.
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[12,21,22]. In agreement with these reports showing the
suppressor role of miR-138, we have also observed
down-regulation of miR-138 in CRC tissues and cell
lines. Restoration of miR-138 can reduce CRC cell col-
ony formation, migration and invasion in vitro. Import-
antly, in vivo metastatic models revealed a significant
decrease in tumor growth and metastatic capability
treated with the stable cell lines which over-expressed
miR-138. To our knowledge, this is the first study show-
ing that miR-138 is down-regulated in CRC tissues and
cell lines and overexpression of miR-138 can inhibit
CRC migration and invasion in vitro and in vivo.
Previous studies indicated that miR-138 may have an
effect on tumor metastasis by targeting SOX4 and Hif1a
in ovarian cancer, MMP2/MMP9 in cholangiocarcinoma
cells and FAK in hela cells [12,22,23]. In our study, we
reported that TWIST2 is a direct target of miR-138.
Overexpression of miR-138 can reduce CRC cell motility
through targeting TWIST2. Meanwhile, we found that
exogenous miR-138 expression or ablation of TWIST2
can both abrogate the metastasis of CRC cells and inhib-
ition of miR-138 can promote the metastatic ability of
CRC cells in vitro (data not shown). In addition, in vivo
metastatic experiments confirmed that stable over-
expression of miR-138 inhibited the metastatic ability of
CRC cells.
To identify the putative miR-138 target genes, we ap-
plied combined in silico seed site analysis, Western Blot,
and luciferase reporter assays. We demonstrated thatTWIST2 is a direct target of miR-138, with the evidence
that overexpression of miR-138 led to reduced luciferase
activity with TWIST2 3′UTR and miR-138 can down-
regulate TWIST2 mRNA and protein expression (Figure 3).
Although the previous studies found that SOX4, Hif1a,
and MMP2/MMP9 are all miR-138′s targets. In our study,
we found that TWIST2 is a novel target of miR-138. We
speculated that the same microRNA performs different
functions through distinct target genes depending on the
tissue or cell types.
Furthermore, we also noticed that overexpression of
TWIST2 by the pcDNA3.1-TWIST2 plasmid nullifies
the effect of suppression of cell invasion by miR-138.
Noticeably, the proliferative and invasive capacity of
TWIST2 overexpression alone is not significantly chan-
ged in CRC cells (data not shown). Knockdown of
TWIST2 gene expression by siRNA had an effect on
in vitro invasion capability that was similar to that of the
restoration of miR-138. These properties support the no-
tion that TWIST2 repression contributes to the tumor
metastasis suppressive effects of miR-138. However, the
suppressive effect of miR-138 on invasion is stronger
than its effect in suppressing TWIST2 expression. This
indicates that there might be additional miR-138 targets
that act as tumor oncogenes. These findings suggest that
miR-138 playing the tumor suppressive role is at least
partly through decreasing the TWIST2 expression.
TWIST2 is a basic helix-loop-helix (bHLH) transcrip-
tion factors have been implicated in cell lineage deter-
mination and differentiation. The protein encoded by
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larity with another bHLH transcription factor, Twist
[24]. It was reported as an oncogene that correlates with
poor prognosis in head and neck squamous cell carcin-
omas [25] and valuable prognostic marker for CRC [26].
And TWIST2 is also crucial for the EMT of cancer cells
[15,27]. Here, we found that TWIST2 was overexpressed
in CRC tumor tissues compared with adjacent normal
tissues (Figure 3E). Enhanced TWIST2 expression was
also observed in CRC cell lines (data not shown). And
the expression of TWIST2 and miR-138 in CRC tissues
is inversely correlated (Figure 3F). These results inferred
that down-regulation of miR-138 endows the metastatic
potential to CRC cells, promotes the metastasis of CRC.
And we speculate that miR-138 may function as a tumor
metastasis inhibitor through the inhibition of CRC EMT
by targeting TWIST2.
Dysregulated miRNA signatures have been associated
with clinical outcome [28]. The potential clinical appli-
cation of miR-138 in human cancer, especially in CRC
has never been reported. In this study, we extended our
analyses by assaying miR-138 expression in specimens
from 187 human CRC patients. Low-level miR-138 ex-
pression was found to be significantly associated with a
more aggressive tumor phenotype and high preoperative
CEA levels and was also shown to be a strong independ-
ent predictor of a short disease-free survival period and
short overall survival for patients with CRC.Conclusion
We have identified that miR-138 is down-regulated in
CRC. miR-138 suppressed CRC cell migration and inva-
sion, at least in part via inhibition of oncogene TWIST2.
And miR-138 may be a candidate tumor suppressive
miRNA of CRC and might be a new prognostic biomarker
for CRC patients.
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